Serum high-density lipoprotein cholesterol and breast cancer risk by menopausal status, body mass index, and hormonal receptor in Korea

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 2, 2009, Pages 508-515

  Kim, Yeonju ^a   Park, Sue K ^c,d   Han, Wonshik ^d   Kim, Dong Hyun ^b   Hong, Yun Chul ^c   Ha, Eun Hee ^e   Ahn, Sei Hyun ^f   Noh, Dong Young ^d   Kang, Daehee ^c,d   Yoo, Keun Young ^c,d  

^a National Cancer Center   (South Korea)

^b Hallym University   (South Korea)

^c Department of Preventive Medicine ^*  (South Korea)

^d Seoul National University   (South Korea)

^e Ewha Womans University School of Medicine   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; HIGH DENSITY LIPOPROTEIN; PROGESTERONE RECEPTOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HEALTH STATUS; HUMAN; KOREA; MAJOR CLINICAL STUDY; MENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL;

BODY MASS INDEX; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; FEMALE; HUMANS; KOREA; LOGISTIC MODELS; MENOPAUSE; MIDDLE AGED; QUESTIONNAIRES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 60549099737     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0133     Document Type: Article

References (50)

1. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. Version 2.0. Lyon: IARC Press; 2004.
2. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 2004;6:229-39.
3. Kim Y, Choi JY, Lee KM, et al. Dose-dependent protective effect of breast-feeding against breast cancer among ever-lactated women in Korea. Eur J Cancer Prev 2007;16:124-9.
4. Yoo KY, Kang D, Park SK, et al. Epidemiology of breast cancer in Korea: occurrence, high-risk groups, and prevention. J Korean Med Sci 2002;17:1-6.
5. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-91.
6. Song YM, Sung J, Ha M. Obesity and risk of cancer in postmenopausal Korean women. J Clin Oncol 2008;26:3395-402.
7. The Endogenous Hormones Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
8. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 2000;152:514-27.
9. Sanderson M, Shu XO, Jin F, et al. Weight at birth and adolescence and premenopausal breast cancer risk in a low-risk population. Br J Cancer 2002;86:84-8.
10. Weiderpass E, Braaten T, Magnusson C, et al. A prospective study of body size in different periods of life and risk of premenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2004;13:112-7.
11. Pike MC, Spicer DV, Dahmoush L, et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-30.
12. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004;89:2583-9.
13. Kucharska-Newton AM, Rosamond WD, Mink PJ, et al. HDL-cholesterol and incidence of breast cancer in the ARIC cohort study. Ann Epidemiol 2008;18:671-7.
14. Boyd NF, McGuire V. Evidence of association between plasma high-density lipoprotein cholesterol and risk factors for breast cancer. J Natl Cancer Inst 1990;82:460-8.
15. Malin A, Dai Q, Yu H, et al. Evaluation of the synergistic effect of insulin resistance and insulin-like growth factors on the risk of breast carcinoma. Cancer 2004;100:694-700.
16. Renehan AG, Harvie M, Howell A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer 2006;13:273-8.
17. Johansson H, Baglietto L, Guerrieri-Gonzaga A, et al. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer. Breast Cancer Res Treat 2004;88:63-73.
18. Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
19. Rollison DE, Newschaffer CJ, Tao Y, et al. Premenopausal levels of circulating insulin-like growth factor I and the risk of postmeno-pausal breast cancer. Int J Cancer 2006;118:1279-84.
20. Bahl M, Ennis M, Tannock IF, et al. Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study. Breast Cancer Res Treat 2005;94:135-44.
21. Furberg AS, Jasienska G, Bjurstam N, et al. Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study. Cancer Epidemiol Biomarkers Prev 2005;14:33-40.
22. Rotheneder M, Kostner GM. Effects of low- and high-density lipoproteins on the proliferation of human breast cancer cells in vitro: differences between hormone-dependent and hormone-independent cell lines. Int J Cancer 1989;43:875-9.
23. Campbell MJ, Esserman LJ, Zhou Y, et al. Breast cancer growth prevention by statins. Cancer Res 2006;66:8707-14.
24. Cao WM, Murao K, Imachi H, et al. A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res 2004;64:1515-21.
25. National Cholesterol Education Program Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002;106:3143-421.
26. Moorman PG, Hulka BS, Hiatt RA, et al. Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status. Cancer Epidemiol Biomarkers Prev 1998;7:483-8.
27. Agurs-Collins T, Kim KS, Dunston GM, et al. Plasma lipid alterations in African-American women with breast cancer. J Cancer Res Clin Oncol 1998;124:186-90.
28. Michalaki V, Koutroulis G, Syrigos K, et al. Evaluation of serum lipids and high-density lipoprotein subfractions (HDL2, HDL3) in postmenopausal patients with breast cancer. Mol Cell Biochem 2005;268:19-24.
29. Gaard M, Tretli S, Urdal P. Risk of breast cancer in relation to blood lipids: a prospective study of 31,209 Norwegian women. Cancer Causes Control 1994;5:501-9.
30. Ferraroni M, Gerber M, Decarli A, et al. HDL-cholesterol and breast cancer: a joint study in northern Italy and southern France. Int J Epidemiol 1993;22:772-80.
31. Ray G, Husain SA. Role of lipids, lipoproteins and vitamins in women with breast cancer. Clin Biochem 2001;34:71-6.
32. Furberg AS, Veierod MB, Wilsgaard T, et al. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst 2004;96:1152-60.
33. Hoyer AP, Engholm G. Serum lipids and breast cancer risk: a cohort study of 5,207 Danish women. Cancer Causes Control 1992;3:403-8.
34. Hsing AW, Gao YT, Chua S, Jr., et al. Insulin resistance and prostate cancer risk. J Natl Cancer Inst 2003;95:67-71.
35. Yoo KY, Kim Y, Park SK, et al. Lifestyle, genetic susceptibility and future trends of breast cancer in Korea. Asian Pac J Cancer Prev 2006;7:679-82.
36. Canoy D, Wareham N, Luben R, et al. Serum lipid concentration in relation to anthropometric indices of central and peripheral fat distribution in 20,021 British men and women: results from the EPIC-Norfolk population-based cohort study. Atherosclerosis 2006;189:420-7.
37. Stephenson GD, Rose DP. Breast cancer and obesity: an update. Nutr Cancer 2003;45:1-16.
38. Ferretti G, Bacchetti T, Negre-Salvayre A, et al. Structural modifications of HDL and functional consequences. Atherosclerosis 2006;184:1-7.
39. Haddy N, Sass C, Droesch S, et al. IL-6, TNF-α and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis 2003;170:277-83.
40. Burger D, Dayer JM. High-density lipoprotein-associated apolipo-protein A-I: the missing link between infection and chronic inflammation? Autoimmun Rev 2002;1:111-7.
41. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007;120:833-43.
42. Eliassen AH, Colditz GA, Rosner B, et al. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 2005;165:2264-71.
43. Kumar AS, Campbell M, Benz CC, et al. A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes. J Clin Oncol 2006;24:2127; author reply 2127-8.
44. Farina HG, Bublik DR, Alonso DF, et al. Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clin Exp Metastasis 2002;19:551-9.
45. Demierre MF, Higgins PD, Gruber SB, et al. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-42.
46. Bonovas S, Filioussi K, Tsavaris N, et al. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 2006;24:4808-17.
47. Lee JH, Yim SH, Won YJ, et al. Population-based breast cancer statistics in Korea during 1993-2002: incidence, mortality, and survival. J Korean Med Sci 2007;22 Suppl:S11-6.
48. Kuczmarski MF, Kuczmarski RJ, Najjar M. Effects of age on validity of self-reported height, weight, and body mass index: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. J Am Diet Assoc 2001;101:28-34.
49. Kronenberg F, Lobentanz EM, Konig P, et al. Effect of sample storage on the measurement of lipoprotein[a], apolipoproteins B and A-IV, total and high density lipoprotein cholesterol and triglycerides. J Lipid Res 1994;35:1318-28.
50. Holland NT, Smith MT, Eskenazi B, et al. Biological sample collection and processing for molecular epidemiological studies. Mutat Res 2003;543:217-34.